London-based Autolus has shown its next-generation CAR T-cell therapy does not induce some of the severe side effects that have led to deaths in patients treated with CAR T-cell treatments currently on the market. The most common side effect of CAR T-cell therapy is cytokine release syndrome, an inflammatory reaction affecting the whole body that can be deadly when it reaches grade three and four — the most severe forms of the condition. Autolus has designed a new generation of CAR T-cell therapy in which the T cells are modified to prevent excessive activation of the T cells, which can cause toxic side effects. Source: Labiotech 9/12/2019